Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Aeglea BioTherapeutics has raised $210.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2023.
Aeglea BioTherapeutics's investors include RA Capital Management, Venrock, OrbiMed, Ally Bridge Group, Rock Springs Capital.
Aeglea BioTherapeutics is headquartered in Austin, United States.
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Aeglea BioTherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aeglea BioTherapeutics — Funding & Investors." VCBacked, June 22, 2023, https://www.vcbacked.co/company/aeglea-biotherapeutics. Accessed August 14, 2026.
VCBacked. (2023). Aeglea BioTherapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/aeglea-biotherapeutics
{{cite web |title=Aeglea BioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aeglea-biotherapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated